Triamcinolone acetonide
As of the edition of 20 October 2026, Triamcinolone acetonide is a small molecule: marketed, first approved in 1966 (CA); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Kenalog
- First approved
- 31 December 1966 (CA)
- Approvals on record
- 35 in 4 regions
- Holder of the most recent approval
- Bausch Health; 19 holders in all
- Registered trials
- 182, 24 stopped early
- Disease areas
- Eye; Bones, joints and muscles; Skin and connective tissue; Injuries; Hormones; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Triamcinolone acetonide.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 45 | 24 | 8 | 4 |
| Phase 1 | 16 | 12 | 1 | 2 |
| Phase 2 | 43 | 27 | 5 | 6 |
| Phase 3 | 48 | 28 | 5 | 6 |
| Phase 4 | 30 | 13 | 7 | 6 |
| All trials | 182 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Applicant and Acquired holder | 1966 to now |
| Sanofi | Later holder and Lead sponsor of trials | 1982 to now |
| Parnell Pharmaceuticals | Later holder | 1987 to now |
| Bausch Health | Acquired holder | 1996 to now |
| Muro Pharmaceutical | Later holder | 2000 to now |
| Novartis | Later holder and Lead sponsor of trials | 2005 to now |
| Alcon | Later holder and Lead sponsor of trials | 2007 to now |
| AbbVie | Acquired holder and Later holder | 2008 to now |
| Lupin Atlantis | Acquired holder | 2010 to now |
| Pacira Pharmaceuticals | Acquired holder and Lead sponsor of trials | 2012 to now |
| Clearside Biomedical | Later holder and Lead sponsor of trials | 2013 to now |
| Delcor Asset | Acquired holder | 2015 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2018 to now |
| Harrow Eye | Acquired holder | 2024 to now |
| Extrovis | Acquired holder | 2025 to now |
| Pharmobedient Consulting | Acquired holder | 2026 to now |
| Westwood Squibb Pharmaceuticals | Later holder |